Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Vertex Pharmaceuticals

Investors need not be concerned about the FDA's approval delay for Eli Lilly's Alzheimer's drug. Novo Nordisk recently picked up a regulatory win that makes the stock even more attractive.

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation

Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.

Weight loss drug Wegovy is now approved for heart health - but that won't mean broad insurance coverage just yet

Advanced Micro Devices

Amazon

ASML Hld

AstraZeneca

NVIDIA

Toyota Motor

By definition, mega-cap stocks are those which possess a market capitalization above $200 billion. So, investors seeking to turn $10,000 into $1 million through Mega cap companies will be choosing from the top 60 companies on this list.

7 Mega-Cap Stocks That Can Turn $10,000 Into $1 Million

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term

Novo Nordisk primarily focuses on the diabetes and obesity markets with medications like Ozempic and Wegovy. Wegovy was recently granted an extended indication from the FDA to treat cardiovascular disease.

Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic

Global X Health & Wellness Thematic ETF

When many investors hear the word mania, they may think of artificial intelligence (AI) stocks or Bitcoin. Both investments have yielded market-beating returns and have room to run higher.

3 Weight-Loss Stocks to Buy as GLP-1 Mania Takes Hold

Broadcom

Taiwan Semiconductor Manufacturing

Visa

Tesla has fallen behind six other companies in terms of market cap. These alternatives dominate industries, including weight management, payments, and semiconductors.

Move Over, Tesla! These 6 Stocks Could Replace It in the "Magnificent 7"

Hims & Hers Health

LifeMD 

Teladoc

Weightwatchers International Inc.

WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.

Can WeightWatchers Regain Its Mojo after Oprah Steps Down?

A research firm added the European pharmaceutical sector star to its focus list. It was among four stocks earning this status.

Why Novo Nordisk Stock Was a Winner Today

Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Novo Nordisk (NVO) a Strong Momentum Stock: Buy Now?

Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Novo Nordisk (NVO) Rating Upgrade to Buy

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to open an office in India this year to tap innovation and a growing healthcare market, its CEO Kasim Kutay said on Tuesday.

Novo Nordisk-owner to expand in India this year

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True?

Novo Nordisk is one of the leading developers of weight-loss drugs. It just shared some great early-stage clinical trial data from one of its programs.

1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant

Novo Nordisk, the Danish drug maker whose fortunes have soared on the popularity of its GLP-1 agonist drugs, scored a long-sought label expansion for its weight-loss drug Wegovy on Friday, with FDA approving it to reduce the risk of major cardiovascular events in adults who are obese or overweight and have established cardiovascular disease.

Wegovy is no longer just a weight-loss drug

Building a stock investment portfolio isn't easy. One moment, you are tempted to wait for a dip, and another, you want to give in to the temptation of buying a stock at a premium with the hopes that it will generate strong returns.

On the Dip: 3 Stocks to Snatch Up Whenever the Market Stumbles

Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk

Amgen

Pfizer

The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for anti-obesity medications (AOMs) reached $6 billion on an annualized basis.

Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks

Shares of Novo Nordisk recently rose to a new all-time high in response to clinical trial results for an experimental new weight-management drug named amycretin. Amycretin is a potential first-in-class dual GLP-1 and amylin agonist that shrank patients' body weight by a placebo-adjusted 12% after 12 weeks of treatment.

Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?

Johnson & Johnson

Investors' eyes are closely following the massive rally in pharmaceutical stocks amid the red-hot anti-obesity market. In 2024, the projected revenue for the pharma market is estimated to reach $1.15 trillion.

The Top 3 Pharma Stocks to Buy in March2024

Structure Therapeutics Inc

Viking Therapeutics

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

The popular weight-loss drug Wegovy, which has helped millions of Americans shed pounds, can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, federal regulators said Friday.

The FDA approved Wegovy for reducing heart attack and stroke risk in overweight patients

The move confirms that the new class of obesity medications are useful for improving health, not just losing weight.

Weight-loss drug Wegovy approved by FDA to cut heart attack, stroke risk

Novo Nordisk said Friday its weight-loss drug gained FDA approval to cut the risk of heart attack and strokes. Novo Nordisk stock dipped.

Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk

The U.S. FDA has approved Novo Nordisk's Wegovy for use in lowering the risk of stroke and heart attack in overweight or obese adults who are not diabetic, the Danish drugmaker said on Friday.

FDA approves Novo Nordisk's Wegovy for use in reducing heart attack risks

News for Novo Nordisk Stock (NVO)